Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?

References

• Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–507.
   PubMed Web of Science ®Google Scholar
• Messina JP, Brady OJ, Scott TW, et al. Global spread of dengue virus types: mapping the 70 year history. Trends Microbiol. 2014;22(3):138–146.
   PubMed Web of Science ®Google Scholar
• Perera R, Kuhn RJ. Structural proteomics of dengue virus. Curr Opin Microbiol. 2008;11(4):369–377.
   PubMed Web of Science ®Google Scholar
• Dussart P, Baril L, Petit L, et al. Clinical and virological study of dengue cases and the members of their households: the multinational DENFRAME Project. PLoS Negl Trop Dis. 2012;6(1):e1482.
   PubMed Web of Science ®Google Scholar
• Anders KL, Nga le H, Thuy NT, et al. Households as foci for dengue transmission in highly urban Vietnam. PLoS Negl Trop Dis. 2015;9(2):e0003528.
   Web of Science ®Google Scholar
• Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg. 1952;1(1):30–50.
   PubMedGoogle Scholar
• Anderson KB, Gibbons RV, Cummings DA, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis. 2014;209(3): 360–368.
   PubMed Web of Science ®Google Scholar
• Montoya M, Gresh L, Mercado JC, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis. 2013;7(8):e2357.
   PubMed Web of Science ®Google Scholar
• Endy TP, Anderson KB, Nisalak A, et al. Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. PLoS Negl Trop Dis. 2011;5(3):e975.
   PubMed Web of Science ®Google Scholar
• Reich NG, Shrestha S, King AA, et al. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J Royal Society, Interface/the Royal Society. 2013;10(86):20130414.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med. 1970;42(5):350–362.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Kouri G, Martinez E, et al. Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Bull Pan Am Health Organ. 1987;21(3):270–279.
   PubMedGoogle Scholar
• Brien JD, Austin SK, Sukupolvi-Petty S, et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol. 2010;84(20):10630–10643.
   PubMed Web of Science ®Google Scholar
• Shrestha B, Brien JD, Sukupolvi-Petty S, et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 2010;6(4):e1000823.
   PubMed Web of Science ®Google Scholar
• Williams KL, Wahala WM, Orozco S, et al. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology. 2012;429(1):12–20.
   PubMed Web of Science ®Google Scholar
• Yamanaka A, Kotaki T, Konishi E. A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity. J Virol. 2013;87(23):12828–12837.
   PubMed Web of Science ®Google Scholar
• Beltramello M, Williams KL, Simmons CP, et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010;8(3):271–283.
   PubMed Web of Science ®Google Scholar
• Teoh EP, Kukkaro P, Teo EW, et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med. 2012;4(139):139ra183.
   Web of Science ®Google Scholar
• Dejnirattisai W, Wongwiwat W, Supasa S, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015;16(2):170–177.
   PubMed Web of Science ®Google Scholar
• Fibriansah G, Tan JL, Smith SA, et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun. 2015;6:6341.
   PubMed Web of Science ®Google Scholar
• Robinson LN, Tharakaraman K, Rowley KJ, et al. Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope. Cell. 2015;162(3):493–504.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science ( New York, NY). 1988;239(4839):476–481.
   PubMed Web of Science ®Google Scholar
• Halstead SB, Lan NT, Myint TT, et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis. 2002;8(12):1474–1479.
   PubMed Web of Science ®Google Scholar
• Halstead SB, Mahalingam S, Marovich MA, et al. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infectious Diseases. 2010;10(10):712–722.
   PubMed Web of Science ®Google Scholar
• Halstead SB, Larsen K, Kliks S, et al. Comparison of P388D1 mouse macrophage cell line and human monocytes for assay of dengue-2 infection-enhancing antibodies. Am J Trop Med Hyg. 1983;32(1):157–163.
   PubMed Web of Science ®Google Scholar
• Halstead SB, Venkateshan CN, Gentry MK, et al. Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies. Baltimore, Md.: 1950 J Immunology. 1984;132(3):1529–1532.
   PubMed Web of Science ®Google Scholar
• De Alwis R, Williams KL, Schmid MA, et al. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog. 2014;10(10):e1004386.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science ( New York, NY). 2010;328(5979):745–748.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003;60:421–467.
   PubMed Web of Science ®Google Scholar
• Balsitis SJ, Williams KL, Lachica R, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 2010;6(2):e1000790.
   PubMed Web of Science ®Google Scholar
• Ng JK, Zhang SL, Tan HC, et al. First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies. PLoS Pathog. 2014;10(4):e1004031.
   PubMed Web of Science ®Google Scholar
• Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000;181(1):2–9.
   PubMed Web of Science ®Google Scholar
• Libraty DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis. 2002;185(9):1213–1221.
   PubMed Web of Science ®Google Scholar
• Simmons CP, Chau TN, Thuy TT, et al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis. 2007;196(3):416–424.
   PubMed Web of Science ®Google Scholar
• Libraty DH, Acosta LP, Tallo V, et al. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 2009;6(10):e1000171.
   PubMed Web of Science ®Google Scholar
• Mongkolsapaya J, Dejnirattisai W, Xu XN, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. 2003;9(7):921–927.
   PubMed Web of Science ®Google Scholar
• Mangada MM, Rothman AL. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. Baltimore, Md.: 1950 J Immunology. 2005;175(4):2676–2683.
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med. 1994;45:491–503.
   PubMed Web of Science ®Google Scholar
• Green S, Vaughn DW, Kalayanarooj S, et al. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis. 1999;179(4):755–762.
   PubMed Web of Science ®Google Scholar
• Kurane I, Meager A, Ennis FA. Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity. J Exp Med. 1989;170(3):763–775.
   PubMed Web of Science ®Google Scholar
• Bukowski JF, Kurane I, Lai CJ, et al. Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes. J Virol. 1989;63(12):5086–5091.
   PubMed Web of Science ®Google Scholar
• Yauch LE, Zellweger RM, Kotturi MF, et al. A protective role for dengue virus-specific CD8+ T cells. J Immunology. Baltimore, Md.: 1950 2009;182(8):4865–4873.
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Angelo MA, De Azeredo EL, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci USA. 2013;110(22):E2046–2053.
   PubMed Web of Science ®Google Scholar
• Yauch LE, Prestwood TR, May MM, et al. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunology. 2010;185(9):5405–5416. Baltimore, Md.: 1950.
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Bangs DJ, Sidney J, et al. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(31):E4256–E4263.
   Google Scholar
• Crill WD, Hughes HR, Delorey MJ, et al. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One. 2009;4(4):e4991.
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg. 2002;66(3):264–272.
   PubMed Web of Science ®Google Scholar
• Tang WW, Grewal R, Shresta S. Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models. Curr Opin Virol. 2015;13:61–66.
   PubMed Web of Science ®Google Scholar
• Clark KB, Onlamoon N, Hsiao HM, et al. Can non-human primates serve as models for investigating dengue disease pathogenesis?. Front Microbiol. 2013;4:305.
   PubMed Web of Science ®Google Scholar
• Zellweger RM, Shresta S. Mouse models to study dengue virus immunology and pathogenesis. Front Immunol. 2014;5:151.
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet ( London, England). 2012;380(9853):1559–1567.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Eckels KH, Carletti I, et al. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg. 2013;88(1):73–88.
   PubMed Web of Science ®Google Scholar
• George SL, Wong MA, Dube TJ, et al. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded Phase 1 clinical trial. J Infect Dis. 2015;212(7):1032–1041.
   Web of Science ®Google Scholar
• Kirkpatrick BD, Durbin AP, Pierce KK, et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis. 2015;212(5):702–710.
   PubMed Web of Science ®Google Scholar
• McArthur MA, Sztein MB, Edelman R. Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines. 2013;12(8):933–953.
   PubMed Web of Science ®Google Scholar
• Kliks SC, Nimmanitya S, Nisalak A, et al. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg. 1988;38(2):411–419.
   PubMed Web of Science ®Google Scholar
• Endy TP, Nisalak A, Chunsuttitwat S, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis. 2004;189(6):990–1000.
   PubMed Web of Science ®Google Scholar
• Buddhari D, Aldstadt J, Endy TP, et al. Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies. PLoS Negl Trop Dis. 2014;8(10):e3230.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3ʹ-untranslated region. Am J Trop Med Hyg. 2001;65(5):405–413.
   PubMed Web of Science ®Google Scholar
• Vaughn DW, Hoke CH Jr., Yoksan S, et al. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine. 1996;14(4):329–336.
   PubMed Web of Science ®Google Scholar
• Bhamarapravati N, Yoksan S, Chayaniyayothin T, et al. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ. 1987;65(2):189–195.
   PubMed Web of Science ®Google Scholar
• Men R, Bray M, Clark D, et al. Dengue type 4 virus mutants containing deletions in the 3ʹ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol. 1996;70(6):3930–3937.
   PubMed Web of Science ®Google Scholar
• White LJ, Sariol CA, Mattocks MD, et al. An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. J Virol. 2013;87(6):3409–3424.
   PubMed Web of Science ®Google Scholar
• Kanesa-thasan N, Sun W, Kim-Ahn G, et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine. 2001;19(23–24):3179–3188.
   PubMed Web of Science ®Google Scholar
• Guy B, Barban V, Mantel N, et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg. 2009;80(2):302–311.
   PubMed Web of Science ®Google Scholar
• Anderson KB, Gibbons RV, Edelman R, et al. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis. 2011;204(3):442–450.
   PubMed Web of Science ®Google Scholar
• Sun W, Edelman R, Kanesa-Thasan N, et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg. 2003;69(6 Suppl):24–31.
   PubMed Web of Science ®Google Scholar
• Sun W, Cunningham D, Wasserman SS, et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin. 2009;5(1):33–40.
   PubMed Web of Science ®Google Scholar
• Edelman R, Wasserman SS, Bodison SA, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg. 2003;69(6 Suppl):48–60.
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Pugachev K, Zhang Z, et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol. 2004;78(9):4761–4775.
   PubMed Web of Science ®Google Scholar
• Kitchener S, Nissen M, Nasveld P, et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine. 2006;24(9):1238–1241.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet ( London, England). 2014;384(9951):1358–1365.
   PubMed Web of Science ®Google Scholar
• Villar L, Dayan GH, Arredondo-Garcia JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372(2):113–123.
   PubMed Web of Science ®Google Scholar
• Schwartz LM, Halloran ME, Durbin AP, et al. The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine. 2015;33(29):3293–3298.
   PubMed Web of Science ®Google Scholar
• Guy B, Nougarede N, Begue S, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine. 2008;26(45):5712–5721.
   PubMed Web of Science ®Google Scholar
• Harenberg A, Begue S, Mamessier A, et al. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum Vaccin Immunother. 2013;9(11):2317–2325.
   PubMed Web of Science ®Google Scholar
• Dayan GH, Galan-Herrera JF, Forrat R, et al. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in Mexico. Hum Vaccin Immunother. 2014;10(10):2853–2863.
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195–1206.
   PubMed Web of Science ®Google Scholar
• Schmitz J, Roehrig J, Barrett A, et al. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine. 2011;29(42):7276–7284.
   PubMed Web of Science ®Google Scholar
• Yauch LE, Shresta S. Dengue virus vaccine development. Adv Virus Res. 2014;88:315–372.
   PubMed Web of Science ®Google Scholar
• Winkler G, Heinz FX, Kunz C. Characterization of a disulphide bridge-stabilized antigenic domain of tick-borne encephalitis virus structural glycoprotein. J Gen Virol. 1987;68(Pt 8):2239–2244.
   PubMed Web of Science ®Google Scholar
• Roehrig JT, Bolin RA, Kelly RG. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology. 1998;246(2):317–328.
   PubMed Web of Science ®Google Scholar
• Thullier P, Demangel C, Bedouelle H, et al. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol. 2001;82(Pt 8):1885–1892.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Khanna N, Swaminathan S. High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli. Protein Expr Purif. 2004;33(1):80–91.
   PubMed Web of Science ®Google Scholar
• Chin JF, Chu JJ, Ng ML. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infection/Institut Pasteur. 2007;9(1):1–6.
   PubMed Web of Science ®Google Scholar
• Sukupolvi-Petty S, Austin SK, Purtha WE, et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol. 2007;81(23):12816–12826.
   PubMed Web of Science ®Google Scholar
• Megret F, Hugnot JP, Falconar A, et al. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology. 1992;187(2):480–491.
   PubMed Web of Science ®Google Scholar
• Fibriansah G, Tan JL, Smith SA, et al. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med. 2014;6(3):358–371.
   PubMed Web of Science ®Google Scholar
• De Alwis R, Smith SA, Olivarez NP, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA. 2012;109(19):7439–7444.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Hermida L, Bernardo L, et al. Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines. 2010;9(2):137–147.
   PubMed Web of Science ®Google Scholar
• Wahala WMPB, Kraus AA, Haymore LB, et al. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009;392(1):103–113.
   PubMed Web of Science ®Google Scholar
• Clements DE, Coller B-AG, Lieberman MM, et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine. 2010;28(15):2705–2715.
   PubMed Web of Science ®Google Scholar
• Bernardo L, Pavón A, Hermida L, et al. The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice. Vaccine. 2011;29(25):4256–4263.
   PubMed Web of Science ®Google Scholar
• Chiang C-Y, Huang M-H, Hsieh C-H, et al. Dengue-1 envelope protein domain III along with PELC and cpG oligodeoxynucleotides synergistically enhances immune responses. PLoS Negl Trop Dis. 2012;6(5):e1645.
   PubMed Web of Science ®Google Scholar
• Liu G, Song L, Beasley DW, et al. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys. Clinical Vaccine Immunol: CVI. 2015;22(5):516–525.
   PubMed Web of Science ®Google Scholar
• Chiang CY, Huang MH, Pan CH, et al. Induction of robust immunity by the emulsification of recombinant lipidated dengue-1 envelope protein domain III. Microbes Infection/Institut Pasteur. 2013;15(10–11):719–728.
   PubMed Web of Science ®Google Scholar
• Chiang CY, Pan CH, Hsieh CH, et al. Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement. PLoS Negl Trop Dis. 2013;7(9):e2432.
   PubMed Web of Science ®Google Scholar
• Chiang CY, Hsieh CH, Chen MY, et al. Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity. Vaccine. 2014;32(12): 1346–1353.
   PubMed Web of Science ®Google Scholar
• Chiang CY, Liu SJ, Tsai JP, et al. A novel single-dose dengue subunit vaccine induces memory immune responses. PLoS One. 2011;6(8):e23319.
   PubMed Web of Science ®Google Scholar
• Gil L, Lopez C, Lazo L, et al. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. Int Immunol. 2009;21(10):1175–1183.
   PubMed Web of Science ®Google Scholar
• Gil L, Bernardo L, Pavon A, et al. Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice. J Gen Virol. 2012;93(Pt 6):1204–1214.
   PubMed Web of Science ®Google Scholar
• Lazo L, Gil L, Lopez C, et al. Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus. Arch Virol. 2010;155(10):1587–1595.
   PubMed Web of Science ®Google Scholar
• Valdés I, Bernardo L, Gil L, et al. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology. 2009;394(2):249–258.
   PubMed Web of Science ®Google Scholar
• Gil L, Izquierdo A, Lazo L, et al. Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys. Virology. 2014;456-457:70–76.
   PubMed Web of Science ®Google Scholar
• Gil L, Marcos E, Izquierdo A, et al. The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2. Immunol Cell Biol. 2015;93(1):57–66.
   PubMed Web of Science ®Google Scholar
• Suzarte E, Gil L, Valdes I, et al. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys. Int Immunol. 2015;93(Pt 6):1204–1214.
   PubMed Web of Science ®Google Scholar
• Garcia-Machorro J, Lopez-Gonzalez M, Barrios-Rojas O, et al. DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the dengue virus in mice. Hum Vaccin Immunother. 2013;9(11):2326–2335.
   PubMed Web of Science ®Google Scholar
• Kim SH, Yang IY, Jang SH, et al. C5a receptor-targeting ligand-mediated delivery of dengue virus antigen to M cells evokes antigen-specific systemic and mucosal immune responses in oral immunization. Microbes Infection/Institut Pasteur. 2013;15(13):895–902.
   PubMed Web of Science ®Google Scholar
• Coconi-Linares N, Ortega-Davila E, Lopez-Gonzalez M, et al. Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice. Vaccine. 2013;31(19):2366–2371.
   PubMed Web of Science ®Google Scholar
• Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19(12):1597–1608.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787–796.
   PubMed Web of Science ®Google Scholar
• Schellack C, Prinz K, Egyed A, et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine. 2006;24(26):5461–5472.
   PubMed Web of Science ®Google Scholar
• Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. Baltimore, Md.: 1950 J Immunology. 2010;185(10):5677–5682.
   PubMed Web of Science ®Google Scholar
• Turley CB, Rupp RE, Johnson C, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine. 2011;29(32):5145–5152.
   PubMed Web of Science ®Google Scholar
• Zuest R, Valdes I, Skibinski D, et al. Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice. Vaccine. 2015;33(12): 1474–1482.
   PubMed Web of Science ®Google Scholar
• Chen HW, Liu SJ, Li YS, et al. A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Arch Virol. 2013;158(7):1523–1531.
   PubMed Web of Science ®Google Scholar
• Nguyen NL, So KK, Kim JM, et al. Expression and characterization of an M cell-specific ligand-fused dengue virus tetravalent epitope using Saccharomyces cerevisiae. J Biosci Bioeng. 2015;119(1):19–27.
   PubMed Web of Science ®Google Scholar
• Zhao H, Jiang T, Zhou X-Z, et al. Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine. PLoS One. 2014;9(1):e86573.
   PubMed Web of Science ®Google Scholar